Last reviewed · How we verify

Tata Memorial Centre — Portfolio Competitive Intelligence Brief

Tata Memorial Centre pipeline: 0 marketed, 0 filed, 1 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 6 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Curcumin Lozenges Curcumin Lozenges phase 3 Natural product/polyphenol anti-inflammatory agent NF-κB, multiple antioxidant pathways Oncology, Oral health, Anti-inflammatory

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aragon Pharmaceuticals, Inc. · 1 shared drug class
  2. Arvinas Androgen Receptor, Inc. · 1 shared drug class
  3. Astellas Pharma · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. City of Hope Medical Center · 1 shared drug class
  6. Lidds AB · 1 shared drug class
  7. Pfizer Inc. · 1 shared drug class
  8. Triple Hair Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tata Memorial Centre:

Cite this brief

Drug Landscape (2026). Tata Memorial Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tata-memorial-centre. Accessed 2026-06-10.

Related